Pipeline
We are advancing our clinical-stage pipeline of differentiated treatments focused on chronic diseases with unmet need around the globe, including cardiovascular, metabolic and pulmonary conditions.
Program
Indication
Discovery
IND-enabling
Phase 1
Phase 2
Oral GLP-1R Franchise
GSBR-1290
GLP-1R
Next Gen GSBR
Dual GLP-1R / GIPR
Type 2 Diabetes and Obesity
Oral APJR
ANPA-0073
APJR
Cardiopulmonary
Oral LPA1R
LTSE-2578
LPA1R
Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic Area Focus
Chronic diseases are rapidly increasing worldwide, escalating the demand for life-changing medicines. These conditions represent 73% of all deaths worldwide and 60% of the global burden of disease. At Structure, we are determined to transform these devastating figures with innovative, small molecule medicines.
417 Million
suffer from Type 2 Diabetes
46% increase by 2045
90% of T2DM patients are overweight or obese
150 Million
suffer from our cardiopulmonary disease areas of focus
>2x increase in incidence of pulmonary fibrosis over last 30 yrs
Mortality can occur within 3-5 yrs